A Phase III, Single-Arm Multicenter Study of Atezolizumab (Anti-PD-L1 Antibody) in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 09 Nov 2023 Planned End Date changed from 30 Jul 2027 to 31 Aug 2027.
- 09 Nov 2023 Planned primary completion date changed from 15 Apr 2027 to 28 Feb 2027.
- 14 Aug 2023 Planned End Date changed from 30 May 2027 to 30 Jul 2027.